Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease - PubMed (original) (raw)

. 1999 Apr 13;38(15):4720-7.

doi: 10.1021/bi982562p.

Affiliations

• PMID: 10200159
• DOI: 10.1021/bi982562p

Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease

M S Wolfe et al. Biochemistry. 1999.

Abstract

The amyloid beta-protein (Abeta), implicated in the pathogenesis of Alzheimer's disease (AD), is a proteolytic metabolite generated by the sequential action of beta- and gamma-secretases on the amyloid precursor protein (APP). The two main forms of Abeta are 40- and 42-amino acid C-terminal variants, Abeta40 and Abeta42. We recently described a difluoro ketone peptidomimetic (1) that blocks Abeta production at the gamma-secretase level [Wolfe, M. S., et al. (1998) J. Med. Chem. 41, 6-9]. Although designed to inhibit Abeta42 production, 1 also effectively blocked Abeta40 formation. Various amino acid changes in 1 still resulted in inhibition of Abeta40 and Abeta42 production, suggesting relatively loose sequence specificity by gamma-secretase. The alcohol counterparts of selected difluoro ketones also lowered Abeta levels, indicating that the ketone carbonyl is not essential for activity and suggesting that these compounds inhibit an aspartyl protease. Selected compounds inhibited the aspartyl protease cathepsin D but not the cysteine protease calpain, corroborating previous suggestions that gamma-secretase is an aspartyl protease with some properties similar to those of cathepsin D. Also, since the gamma-secretase cleavage sites on APP are within the transmembrane region, we consider the hypothesis that this region binds to gamma-secretase as an alpha-helix and discuss the implications of this model for the mechanism of certain forms of hereditary AD.

PubMed Disclaimer

Similar articles

• Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.
  Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gurney ME. Yan R, et al. Nature. 1999 Dec 2;402(6761):533-7. doi: 10.1038/990107. Nature. 1999. PMID: 10591213
• Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease.
  Wolfe MS, De Los Angeles J, Miller DD, Xia W, Selkoe DJ. Wolfe MS, et al. Biochemistry. 1999 Aug 31;38(35):11223-30. doi: 10.1021/bi991080q. Biochemistry. 1999. PMID: 10471271 Review.
• Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity.
  Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Wolfe MS, et al. Nature. 1999 Apr 8;398(6727):513-7. doi: 10.1038/19077. Nature. 1999. PMID: 10206644
• Identification of a novel aspartic protease (Asp 2) as beta-secretase.
  Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, Smith TS, Simmons DL, Walsh FS, Dingwall C, Christie G. Hussain I, et al. Mol Cell Neurosci. 1999 Dec;14(6):419-27. doi: 10.1006/mcne.1999.0811. Mol Cell Neurosci. 1999. PMID: 10656250
• Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
  Pollack SJ, Lewis H. Pollack SJ, et al. Curr Opin Investig Drugs. 2005 Jan;6(1):35-47. Curr Opin Investig Drugs. 2005. PMID: 15675602 Review.

Cited by

• Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease.
  Mann DM, Pickering-Brown SM, Takeuchi A, Iwatsubo T; Members of the Familial Alzheimer's Disease Pathology Study Group. Mann DM, et al. Am J Pathol. 2001 Jun;158(6):2165-75. doi: 10.1016/s0002-9440(10)64688-3. Am J Pathol. 2001. PMID: 11395394 Free PMC article.
• Haplodeficiency of Cathepsin D does not affect cerebral amyloidosis and autophagy in APP/PS1 transgenic mice.
  Cheng S, Wani WY, Hottman DA, Jeong A, Cao D, LeBlanc KJ, Saftig P, Zhang J, Li L. Cheng S, et al. J Neurochem. 2017 Jul;142(2):297-304. doi: 10.1111/jnc.14048. Epub 2017 May 26. J Neurochem. 2017. PMID: 28429406 Free PMC article.
• A requirement for Notch1 distinguishes 2 phases of definitive hematopoiesis during development.
  Hadland BK, Huppert SS, Kanungo J, Xue Y, Jiang R, Gridley T, Conlon RA, Cheng AM, Kopan R, Longmore GD. Hadland BK, et al. Blood. 2004 Nov 15;104(10):3097-105. doi: 10.1182/blood-2004-03-1224. Epub 2004 Jul 13. Blood. 2004. PMID: 15251982 Free PMC article.
• The initial substrate-binding site of gamma-secretase is located on presenilin near the active site.
  Kornilova AY, Bihel F, Das C, Wolfe MS. Kornilova AY, et al. Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3230-5. doi: 10.1073/pnas.0407640102. Epub 2005 Feb 18. Proc Natl Acad Sci U S A. 2005. PMID: 15722417 Free PMC article.
• Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies.
  Evin G, Sernee MF, Masters CL. Evin G, et al. CNS Drugs. 2006;20(5):351-72. doi: 10.2165/00023210-200620050-00002. CNS Drugs. 2006. PMID: 16696577 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Chemical Society

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information